Gao Dongxia, Lu Yu, Lu Yingzhi, Wang Yuping, Zhang Bo, Wu Bingquan
Department of pathology, Health Science Center of Peking University, Beijing, 100083, China (Email:
Zhonghua Bing Li Xue Za Zhi. 2002 Jun;31(3):268-70.
To investigate expression of Her-2/neu (c-erbB-2) and its significance in ovarian epithelial tumors.
106 specimens and clinical history of ovarian epithelial tumors were collected including 54 cases of malignant, 33 cases of borderline and 19 benign cases. There were 19 cases of stages I and II and 35 cases of stages III and IV in ovarian carcinoma and all borderline malignant cases were stage I according to FIGO's standard. Immunohistochemical staining for Her-2/neu was performed by LSAB method.
The positives rates of Her-2/neu of benign, borderline and malignant tumors were 47.4% (9/19), 84.8% (28/33,), and 85.2% (46/54), respectively. Both borderline and malignant cases were found to have higher expression of Her-2/neu than those of benign cases (P < 0.02 and P < 0.01) respectively. Overexpression of Her-2/neu showed in 14/54 (25.9%) of malignant cases, 3/33 (9.1%) of borderline, and none of benign cases. Overexpression of Her-2/neu in malignant tumors cases with metastasis was higher than those without metastasis (P < 0.001).
Overexpression of Her-2/neu is associated with biological aggressiveness of ovarian cancer.
探讨Her-2/neu（c-erbB-2）在卵巢上皮性肿瘤中的表达及其意义。
收集106例卵巢上皮性肿瘤标本及临床资料，其中恶性54例，交界性33例，良性19例。卵巢癌中Ⅰ、Ⅱ期19例，Ⅲ、Ⅳ期35例，所有交界性恶性病例按FIGO标准均为Ⅰ期。采用LSAB法进行Her-2/neu免疫组化染色。
良性、交界性和恶性肿瘤Her-2/neu阳性率分别为47.4%（9/19）、84.8%（28/33）和85.2%（46/54）。交界性和恶性病例Her-2/neu表达均高于良性病例（P分别<0.02和P<0.01）。恶性病例中14/54（25.9%）、交界性病例中3/33（9.1%）有Her-2/neu过表达，良性病例无。有转移的恶性肿瘤病例Her-2/neu过表达高于无转移者（P<0.001）。
Her-2/neu过表达与卵巢癌的生物学侵袭性相关。
